Athens Research/Cambio - Excellence in Molecular Biology/10 pouches/MC-12-9154-10

价格
面议
货号:MC-12-9154-10
浏览量:85
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Lab Reagents

Lab Reagents: Smart Buffers and Reagents

Biological buffers for the life science laboratory need to meet a wide array of criteria. These include good stability, lack of toxicity, precision in pH, pKa between 6.0 and 8.0 (the region in which most biological reactions occur), minimal salt effects due to the ionic composition of the solution, free of enzymatic and hydrolytic activity and minimal participation in biological reactions. Buffers for molecular biology applications, e.g. Tris-Borate-EDTA and Tris-Acetate-EDTA, need to be free from DNAse and RNAse activity. Medicago"s SmartBuffers meet all these criteria. They are manufactured using highly purified, analytical grade chemicals and are extensively quality tested. Manufacturing is done in a controlled clean environment according to GMP procedures. A high level of automation essentially avoids operator intervention and contact with the products. SmartBuffers are supplied as exactly pre-weighed tablets packed in containers or blister packs or as exactly pre-weighed powder mixes packed in sealed aluminium foil pouches. •Pre-mixed powder buffers or tablets with pre-set pH•Analytical grade reagents •Eliminates calculation, formulation and weighing errors •Dissolve-and-go for greater convenience •Stable at room temperature for at least 3 years •Guaranteed reproducibility

  • Catalogue
  • Description
  • Notes

Tris-EDTA (TE) Buffer 10x, pH 7.4

TE buffer is composed by Tris, a buffering agent and EDTA, a chelating agent. EDTA has the ability to prevent degradation of DNA and RNA by chelating magnesium- or other divalent metal ions.Tris-EDTA-based solutions break protein cross-links and can therefore unmask antigens and epitopes in formalin-fixed and paraffin-embedded tissue sections. Treatment with TE buffer enhances the staining intensity of antibodies in the immuno-histochemical detection of certain proteins.

Medicago AB

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
MC-12-9154-10Tris-EDTA buffer (TE) 10x pH 7.4, 1000 ml10 pouches£113.00QuantityAdd to Order

Tris-EDTA (TE) Buffer 10x, pH 7.4

TE buffer is composed by Tris, a buffering agent and EDTA, a chelating agent. EDTA has the ability to prevent degradation of DNA and RNA by chelating magnesium- or other divalent metal ions.Tris-EDTA-based solutions break protein cross-links and can therefore unmask antigens and epitopes in formalin-fixed and paraffin-embedded tissue sections. Treatment with TE buffer enhances the staining intensity of antibodies in the immuno-histochemical detection of certain proteins.

Medicago AB

Product description

TE buffer is composed by Tris, a buffering agent and EDTA, a chelating agent. EDTA has the ability to prevent degradation of DNA and RNA by chelating magnesium- or other divalent metal ions.Tris-EDTA-based solutions break protein cross-links and can therefore unmask antigens and epitopes in formalin-fixed and paraffin-embedded tissue sections. Treatment with TE buffer enhances the staining intensity of antibodies in the immuno-histochemical detection of certain proteins.

Medicago’s TE buffer is supplied as exactly pre-weighed powder in pouches, giving 1000 ml of 0.1 M Tris-HCl, 0.010 M Tris-EDTA buffer with pH 7.4 at 25°C when dissolved in nuclease free water or deionized water.

Features

  • pH adjusted for DNA/RNA work
  • Sterilize by autoclaving or filtration
  • Contains chelating agent
  • 10x pre-weighed powder mix in pouches
  • Dissolve and go for greater convenience

Directions for use

Empty one pouch of the TE buffer in a laboratory flask or beaker placed on a magnetic stirrer. Add 300 ml of deionized water and stir the solution for a few minutes. Adjust the volume up to 1000 ml, stir until full dissolution and the buffer solution is ready to use.

Shipping and storage

TE buffer is shipped at room temperature. Store the pouches in a dry place at room temperature. Shelf life is three years after production date.

Specifications

Chemical: Analytical grade

Format: Exactly pre-weighed powder mix

Concentration: 0.1 M Tris-HCl, 0.010 M EDTA

Volume: 1000 ml

pH: 7.4 ± 0.05 at 25°C

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Tris-EDTA (TE) Buffer 10x, pH 7.4

TE buffer is composed by Tris, a buffering agent and EDTA, a chelating agent. EDTA has the ability to prevent degradation of DNA and RNA by chelating magnesium- or other divalent metal ions.Tris-EDTA-based solutions break protein cross-links and can therefore unmask antigens and epitopes in formalin-fixed and paraffin-embedded tissue sections. Treatment with TE buffer enhances the staining intensity of antibodies in the immuno-histochemical detection of certain proteins.

Medicago AB

Applications

  • Storing and diluting DNA and RNA
  • Breaking protein-links in immuno-histochemistry procedures

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.